Global Vaccine Market Forecast to 2012

Abstract

“Global Vaccine Market Forecast to 2012”, our new research report, states that vaccines, which were earlier thought as a low margin, low growth industry, have emerged as one of the most lucrative segments in the pharmaceutical industry. With a projected CAGR growth of over 16% in the next five years, the industry will emerge as the fastest growing therapy area. The US and Europe represents the two largest vaccine markets (in fact, these tow countries were the largest markets in 2007) and will continue to experience healthy growth in future.

Segment-wise, pediatric vaccines presently dominate the global vaccine market but adult vaccine segments will define the future direction of growth. The cancer vaccine marker, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers. Overall, cancer vaccines are expected to account for nearly 27% of the total vaccine revenues by 2012.

Owing to lower margins and the mature nature of these markets, the basic and enhanced pediatric markets are expected to show stagnant growth in future. On the other hand, launch of a number of new vaccines will make the addiction, cancer and proprietary pediatrics/adolescent vaccine market highly dynamic. On a whole, the global vaccine market is expected to register revenues in excess of US$ 30 Billion by 2012.

Analysis of the competitive landscape of the market shows its highly concentrated structure, with the top four players accounting for over 86% of the total market in 2007.

Our report gives an extensive and objective analysis on the global market for vaccines. It investigates both the past and current trends in the vaccine market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of vaccines, both in the market and in developing stage. Based on various present and future indicators, the report evaluates the prospects of various vaccine segments. The report can thus give valuable information for manufacturers/investors preparing to enter in these vaccine segments.

• Global vaccine revenues
• Basic pediatrics revenues
• Enhanced pediatrics revenues
• Proprietary pediatrics/adolescent revenues
• Adult/travel revenues
• Influenza revenues
• Cancer vaccines revenues
• Major pediatric and adult vaccines
• Major geographical markets - US, Europe, China, India, Japan and Brazil
• US pediatric and adult vaccine markets
• Revenues of key players
• Revenues of key vaccine brands

Profiling on Key Players

This section gives a category-wise overview on the key players, including Sanofi-Aventis, GlaxoSmithKline and Novartis, operating in the global vaccine market. It provides vital information, like business overview, current performance, future prospects of key vaccine brands and major merger and acquisitions by the key players to give a rational overview on the competitive landscape of the market.